Telix Pharmaceuticals Limited
TLX.ASXHealth Care
Development and commercialising molecularly targeted radiation products for the treatment of cancer.
Market Data
$13.120
+0.0%$4.4B
-100000.0x
$-0.029
0.00%
-0.3%
Latest Earnings
2025 Full Year Results Announcement
20 February 2026
Telix Pharmaceuticals delivered strong revenue growth of 56% to US$803.8M in FY2025, beating their upgraded guidance, while investing heavily in R&D pipeline development. Despite positive adjusted EBITDA of US$39.5M, the company reported a small pre-tax loss of US$5.3M due to finance costs and acquisition-related expenses. Management provided optimistic FY2026 guidance of US$950-970M revenue, reflecting continued confidence in their commercial platform and therapeutic pipeline. Key points: Revenue up 56% to US$803.8M, exceeding upgraded full year guidance of US$800-820M; Precision Medicine segment revenue up 22% with stable 64% gross margins and 24% increase in adjusted EBITDA to US$216.4M; Strong R&D pipeline progress with three pivotal stage trials initiated in prostate, kidney and brain cancer
Recent Announcements
Becoming a substantial holder
Citigroup Global Markets Australia Pty Limited (ACN 003 114 832) became a substantial holder (5.9153%).
Becoming a substantial holder from CGF
CGF became a substantial holder (5.24%).
Ceasing to be a substantial holder
Citigroup Global Markets Australia Pty Limited (ACN 003 114 832) ceased to be a substantial holder.
Becoming a substantial holder
Citigroup Global Markets Australia Pty Limited (ACN 003 114 832) became a substantial holder (5.3084%).
Ceasing to be a substantial holder from CGF
CGF ceased to be a substantial holder.
Ceasing to be a substantial holder
Citigroup Global Markets Australia Pty Limited (ACN 003 114 832) ceased to be a substantial holder.
Becoming a substantial holder
Citigroup Global Markets Australia Pty Limited (ACN 003 114 832) became a substantial holder (5.0639%).
Becoming a substantial holder from CGF
CGF became a substantial holder (5.05%).
2025 Full Year Results Announcement
Telix Pharmaceuticals delivered strong revenue growth of 56% to US$803.8M in FY2025, beating their upgraded guidance, while investing heavily in R&D pipeline development. Despite positive adjusted EBITDA of US$39.5M, the company reported a small pre-tax loss of US$5.3M due to finance costs and acquisition-related expenses. Management provided optimistic FY2026 guidance of US$950-970M revenue, reflecting continued confidence in their commercial platform and therapeutic pipeline. Key points: Revenue up 56% to US$803.8M, exceeding upgraded full year guidance of US$800-820M; Precision Medicine segment revenue up 22% with stable 64% gross margins and 24% increase in adjusted EBITDA to US$216.4M; Strong R&D pipeline progress with three pivotal stage trials initiated in prostate, kidney and brain cancer
2025 Full Year Results Presentation
Telix Pharmaceuticals reported strong FY25 results with revenue growing 56% to $804M, driven by 22% growth in Precision Medicine to $622M and full-year consolidation of RLS acquisition. Group EBITDA was $40M with positive cash balance of $142M, while the company advanced four assets into pivotal/Phase 3 trials and provided FY26 revenue guidance of $950-970M. Key points: Strong 56% revenue growth to $804M meeting increased guidance range; Precision Medicine revenue up 22% to $622M with 64% gross margin maintained; Four therapeutics assets advanced to pivotal/Phase 3 trials including TLX591-Tx and TLX101-Tx
Get real-time alerts for TLX
Receive AI-powered earnings summaries and instant notifications when Telix Pharmaceuticals Limited releases results.
Register Free